Dalcetrapib Reduces Risk of New-Onset Diabetes in Patients With Coronary Heart Disease.

ABSTRACT:

Objective

Incident type 2 diabetes is common among patients with recent acute coronary syndrome and is associated with an adverse prognosis. Some data suggest that cholesteryl ester transfer protein (CETP) inhibitors reduce incident type 2 diabetes. We compared the effect of treatment with the CETP inhibitor dalcetrapib or placebo on incident diabetes in patients with recent acute coronary syndrome.

Research design and methods

In the dal-OUTCOMES trial, 15,871 patients were randomly assigned to treatment with dalcetrapib 600 mg daily or placebo, beginning 4-12 weeks after an acute coronary syndrome. Absence of diabetes at baseline was based on medical history, no use of antihyperglycemic medication, and hemoglobin A_1c and serum glucose levels below diagnostic thre

SUBMITTER: Schwartz GG 

PROVIDER: S-EPMC7171952 | biostudies-literature | 2020 May

REPOSITORIES: biostudies-literature